Altre lingue Protagenic Therapeutics, Inc.

Azioni

PTIX

US74365N2027

Tempo differito Nasdaq Altri mercati azionari 18:13:55 24/04/2024			Variaz. 5gg	Var. 1 gen.
1,39 ^USD	-11,46%		+2,96%	+40,40%

01/04	Protagenic Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
27/03	Protagenic Therapeutics conclude con successo la terza coorte nella porzione a dose singola dello studio di Fase 1 per i disturbi neuropsichiatrici legati allo stress.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	27/03
Protagenic Therapeutics, Inc.	21/03
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	14/02
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	13/02
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	12/12
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	31/03/23
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23
PROTAGENIC THERAPEUTICS, INC.NEW : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22/03/23
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	29/11/22
PROTAGENIC THERAPEUTICS, INC.NEW : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	29/11/22
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	14/11/22
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)	02/09/22
PROTAGENIC THERAPEUTICS, INC.NEW Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	11/08/22
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Protagenic Therapeutics, Inc.

Azioni

PTIX

US74365N2027

Altre lingue

Filtri